Catalent, Inc. (NYSE:CTLT) acquired Commercial-Scale Cell Therapy Development and Manufacturing Facility of Erytech Pharma for $44.5 million on April 25, 2022. ERYTECH’s current staff at the site of approximately 40 people will transfer to Catalent's employment and Catalent is developing its plans for its future recruitment needs. ERYTECH’s board of directors has unanimously approved the transaction. ERYTECH’s board of directors has established an ad hoc committee in order to review the indications of interests received by ERYTECH and to issue a recommendation to its board of directors. Duane Morris served as legal counsel to Catalent. Cooley LLP and Gide Loyrette Nouel A.A.R.P.I. served as legal counsel to ERYTECH. Torreya Capital LLC served as exclusive financial advisor to ERYTECH. Catalent, Inc. (NYSE:CTLT) completed the acquisition of Commercial-Scale Cell Therapy Development and Manufacturing Facility of Erytech Pharma on April 25, 2022.